LSE:GSKPharmaceuticals
How Should Investors View GSK’s Valuation After Its Strong 2025 Share Price Rally?
If you are wondering whether GSK is still a smart buy after its big run or if most of the upside is already priced in, this article will help you frame that decision through a valuation lens.
Despite a minor 0.5% slip over the last week, GSK is still up 1.4% over 30 days, 33.1% year to date and 43.1% over the past year, which naturally raises the question of whether the current price fairly reflects its prospects.
That strong share price performance has come as investors have refocused on...